Changes in pharmaceutical industry payments to physicians after New Jersey's 2018 restriction
Health Affairs Scholar · 07.01.2026 · 4 (1)
DOI: 10.1093/haschl/qxaf254 ↗Kurz gefasst
Fachartikel in der Zeitschrift Health Affairs Scholar, online erschienen am 30.12.2025. Verfasst von Neeraj G Patel und 2 weiteren Autor:innen. Beteiligte Einrichtung: Yale School of Medicine, New Haven, CT 06510, United States. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 7 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Yale School of Medicine.
Abstract (Originalsprache)
The federal government and several states have implemented measures to restrict, ban, and increase transparency of promotional payments from pharmaceutical companies to clinicians who prescribe medications. In 2018, New Jersey adopted a novel rule that included a $10 000 restriction on aggregate annual prescriber compensation for promotional speaking, advisory board participation, and consulting arrangements. In this study, we estimated changes associated with the restriction by comparing payments made to physicians in New Jersey to those in a comparator state, Pennsylvania, where no such rule exists. We found that the New Jersey restriction was associated with no significant difference in the proportion of physicians receiving aggregate honoraria and consulting payments above $10 000 annually as compared to physicians in Pennsylvania. Further research is needed to better understand the effect of state policies restricting pharmaceutical industry payments to prescribers.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Yale School of Medicine, New Haven, CT 06510, United States.
- Department of Internal Medicine, Section of General Medicine, Yale School of Medicine, New Haven, CT 06510, United States.
- Yale Collaboration for Regulatory Rigor, Integrity, and Transparency, Yale School of Medicine, New Haven, CT 06510, United States.
- Department of Health Policy and Management, Yale School of Public Health, New Haven, CT 06510, United States.
ORCID-Profile: Neeraj G Patel, Reshma Ramachandran, Joseph S Ross
Förderung
- Yale School of Medicine
Zitieren
APA
Patel, N. G., Ramachandran, R., & Ross, J. S. (2026). Changes in pharmaceutical industry payments to physicians after New Jersey's 2018 restriction. Health Affairs Scholar, 4(1). https://doi.org/10.1093/haschl/qxaf254
Vancouver
Patel NG, Ramachandran R, Ross JS. Changes in pharmaceutical industry payments to physicians after New Jersey's 2018 restriction. Health Affairs Scholar. 2026;4(1). doi:10.1093/haschl/qxaf254
BibTeX
@article{Patel2026,
author = {Patel, Neeraj G and Ramachandran, Reshma and Ross, Joseph S},
title = {Changes in pharmaceutical industry payments to physicians after New Jersey's 2018 restriction},
journal = {Health Affairs Scholar},
year = {2026},
volume = {4},
number = {1},
doi = {10.1093/haschl/qxaf254}
}
EUVIMED